Skip to main content
Clinical Trials/TCTR20130528001
TCTR20130528001RecruitingPhase 2

Pentoxifylline and Metformin versus Placebo for The Treatment of Patients with Nonalcoholic steatohepatitis, A Randomized, Double-Blinded, Placebo- Controlled Clinical Trial.

The Gastroenterological Association of Thailand0 sites38 target enrollmentStarted: May 28, 2013Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Enrollment
38

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 Years to 70 Years (—)
Sex
All

Inclusion Criteria

  • 1. biopsy proven NASH performed within 2 year of entry
  • 2. ALT > 1.5 times of ULN and repeated at least twice over 6 months
  • 3. life style modification in the outpatient clinic for up to 3 months and persistent ALT elevation
  • 4. Not taking metformin or PTX at least 3 month prior to entry
  • 5. type 2 DM Patients included only if on oral hypoglycemic drug and with hemoglobin A1C <8%

Exclusion Criteria

  • 1. Alcohol intake > 20gm/day in men and 10 gm/day in women for 2 years
  • Other chronic liver diseases
  • 2. Decompensated cirrhosis
  • 3. Secondary steatohepatitis e.g. drug
  • (tamoxifen, methotrexate, amiodarone, valproate, glucocorticoid)
  • 4. Taking medications that have shown benefits in previous NASH studies e.g. pioglitazone, Vitamin E, Folic acid, UDCA, Omega 3, NAC
  • Cr > 1.5mg/dl
  • 5. A history of drug allergy to PTX or methylxanthines (caffeine, theophylline) and metformin
  • 6. Risk of bleeding tendency
  • 7. Pregnancy
  • 8. Refuse Liver biopsy

Investigators

Similar Trials